Literature DB >> 10970697

Pulmonary availability of isotretinoin in rats after inhalation of a powder aerosol.

S M Raleigh1, R D Verschoyle, C Bowskill, U Pastorino, J N Staniforth, F Steele, D Dinsdale, P Carthew, C K Lim, J Silvester, A Gescher.   

Abstract

Repeated oral administration of chemopreventive retinoids such as isotretinoin over extended periods of time is associated with intolerable systemic toxicity. Here isotretinoin was formulated as a powder aerosol, and its delivery to the lungs of rats was studied with the aim to explore the possibility of minimizing adverse effects associated with its oral administration. Rats received isotretinoin orally (0.5, 1 or 10 mg kg(-1)) or by inhalation (theoretical dose approximately 1 or approximately 10 mg kg(-1)) in a nose-only inhalation chamber. Isotretinoin was quantitated by high-pressure liquid chromatography in plasma and lung tissue. The ratios of mean area of concentration-vs-time curve (AUC) values in the lungs over mean AUCs in the plasma for isotretinoin following single or repeated aerosol exposure surpassed those determined for the oral route by factors of between two (single low-dose) and five (single high-dose). Similarly, the equivalent ratios for the maximal peak concentrations in lungs and plasma obtained after aerosol exposure consistently exceeded those seen after oral administration, suggesting that lungs were exposed to higher isotretinoin concentrations after aerosol inhalation than after oral administration of similar doses. Repeated high doses of isotretinoin by inhalation resulted in moderate loss of body weight, but microscopic investigation of ten tissues including lung and oesophagus did not detect any significant aerosol-induced damage. The results suggest that administration of isotretinoin via powder aerosol inhalation is probably superior to its application via the oral route in terms of achieving efficacious drug concentrations in the lungs. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10970697      PMCID: PMC2374686          DOI: 10.1054/bjoc.2000.1421

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Phase II study of isotretinoin in the treatment of advanced non-small cell lung cancer.

Authors:  S M Grunberg; L M Itri
Journal:  Cancer Treat Rep       Date:  1987-11

2.  Comparative subchronic toxicity of all-trans- and 13-cis- retinoic acid in Sprague--Dawley rats.

Authors:  E J Hixson; J A Burdeshaw; E P Denine; S D Harrison
Journal:  Toxicol Appl Pharmacol       Date:  1979-02       Impact factor: 4.219

3.  Disposition of 13-cis-retinoic acid and N-(2-hydroxyethyl)retinamide in mice after oral doses.

Authors:  J R Kalin; M J Wells; D L Hill
Journal:  Drug Metab Dispos       Date:  1982 Jul-Aug       Impact factor: 3.922

Review 4.  Antiasthma drug delivery. What is on the horizon?

Authors:  J C Virchow; C Kroegel; H Matthys
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

5.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck.

Authors:  W K Hong; S M Lippman; L M Itri; D D Karp; J S Lee; R M Byers; S P Schantz; A M Kramer; R Lotan; L J Peters
Journal:  N Engl J Med       Date:  1990-09-20       Impact factor: 91.245

6.  Aerosol delivery of liposomal all-trans-retinoic acid to the lungs.

Authors:  R Parthasarathy; B Gilbert; K Mehta
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

7.  13-cis-retinoic acid in the treatment of oral leukoplakia.

Authors:  W K Hong; J Endicott; L M Itri; W Doos; J G Batsakis; R Bell; S Fofonoff; R Byers; E N Atkinson; C Vaughan
Journal:  N Engl J Med       Date:  1986-12-11       Impact factor: 91.245

8.  Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia.

Authors:  J S Lee; S M Lippman; S E Benner; J J Lee; J Y Ro; J M Lukeman; R C Morice; E J Peters; A C Pang; H A Fritsche
Journal:  J Clin Oncol       Date:  1994-05       Impact factor: 44.544

9.  Growth suppression of transformed human bronchial epithelial cells by all-trans-retinoic acid occurs through specific retinoid receptors.

Authors:  M J Ahn; J Langenfeld; M M Moasser; V Rusch; E Dmitrovsky
Journal:  Oncogene       Date:  1995-12-07       Impact factor: 9.867

10.  Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin.

Authors:  R Lotan; X C Xu; S M Lippman; J Y Ro; J S Lee; J J Lee; W K Hong
Journal:  N Engl J Med       Date:  1995-05-25       Impact factor: 91.245

View more
  2 in total

1.  Uptake of all-trans retinoic acid-containing aerosol by inhalation to lungs in a guinea pig model system--a pilot study.

Authors:  Michael W Schäffer; Somdutta Sinha Roy; Shyamali Mukherjee; David E Ong; Salil K Das
Journal:  Exp Lung Res       Date:  2010-12       Impact factor: 2.459

2.  Could isotretinoin be a protective agent against COVID-19?: A dermatologist perspective.

Authors:  Ayman Abdelmaksoud; Anant Patil; Recep Dursun; Selami Aykut Temiz; Erhan Ayhan; Mohamad Goldust; Michelangelo Vestita
Journal:  J Cosmet Dermatol       Date:  2021-06-06       Impact factor: 2.189

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.